Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen.

We describe a platform for dual modality (radionuclide/optical) imaging of prostate cancer (PCa) based on targeting the prostate-specific membrane antigen (PSMA). An example provided demonstrates that after a single intravenous (IV) injection of tracer amounts (0.1 nmol) of imaging agent to a tumor-bearing mouse, both single photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) imaging were capable of delineating tumor specifically. That such small injected amounts could identify tumor in vivo suggests that optical agents, as has long been known for radiopharmaceuticals, may obey the tracer principle, enabling more rapid clinical translation.

[1]  Fijs W B van Leeuwen,et al.  Multimodal tumor-targeting peptides functionalized with both a radio- and a fluorescent label. , 2010, Bioconjugate chemistry.

[2]  S. Achilefu,et al.  Multimodality Imaging of Gene Transfer with a Receptor-Based Reporter Gene , 2010, The Journal of Nuclear Medicine.

[3]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[4]  Martin G Pomper,et al.  68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. , 2010, Journal of medicinal chemistry.

[5]  M. Pomper,et al.  Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma. , 2010, Cancer research.

[6]  A. Alavi,et al.  Non-FDG PET in the practice of oncology. , 2010, Indian journal of cancer.

[7]  Martin G Pomper,et al.  A low molecular weight PSMA-based fluorescent imaging agent for cancer. , 2009, Biochemical and biophysical research communications.

[8]  Martin G Pomper,et al.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. , 2009, Cancer research.

[9]  Samuel Achilefu,et al.  Complementary optical and nuclear imaging of caspase-3 activity using combined activatable and radio-labeled multimodality molecular probe. , 2009, Journal of biomedical optics.

[10]  M. Pomper,et al.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. , 2008, Journal of medicinal chemistry.

[11]  Martin G Pomper,et al.  Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). , 2008, Journal of medicinal chemistry.

[12]  Martin G. Pomper,et al.  Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA) , 2008, Cancer biology & therapy.

[13]  J. Seidel,et al.  N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer , 2008, Clinical Cancer Research.

[14]  A. Rajasekaran,et al.  Clinical trials of cancer therapies targeting prostate-specific membrane antigen. , 2007, Reviews on recent clinical trials.

[15]  Matthias D Hofer,et al.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.

[16]  S. Vallabhajosula,et al.  Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Pomper,et al.  Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer , 2005, Clinical Cancer Research.

[18]  J. Neale,et al.  NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR , 2004, Journal of neurochemistry.

[19]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[20]  William C. Olson,et al.  The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[22]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.